C1 Esterase Inhibitor Subcutaneous (Human) (Haegarda)
C1 Esterase Inhibitor Subcutaneous (Human) is an FDA-licensed reference biologic from CSL Behring GmbH.
Reference product
Haegarda C1 Esterase Inhibitor Subcutaneous (Human)
CSL Behring GmbH
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Molecular structure
Experimental 3D structure for C1 Esterase Inhibitor Subcutaneous (Human) from the RCSB Protein Data Bank (PDB 5DU3).

Interactive biological assembly from PDB entry 5DU3. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.
Exclusivity & patent cliffs
Reference approval
Approval date of the reference C1 Esterase Inhibitor Subcutaneous (Human) product.
9 yr 7 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
2 yr 5 mo ago
C1 Esterase Inhibitor Subcutaneous (Human): frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for C1 Esterase Inhibitor Subcutaneous (Human).
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about C1 Esterase Inhibitor Subcutaneous (Human)
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo
